已经建立了人类胃肠系统微流控器官模型，以重现足够的微环境来研究生理学和病理生理学。为了找到更逼真的系统和成本更低的药物筛选或基础研究模型，胃肠系统微流控器官模型（GOoC）成为有前途的临床前体外模型。这一进展建立在生物打印、微流控和器官模型研究等多种技术的最新发展基础上。在本综述中，我们将重点讨论以下健康和疾病模型：人类肠道微生物群-微流控芯片及其与胃肠病理生理学的关联；胃-微流控芯片、肝-微流控芯片、胰腺-微流控芯片、小肠、结肠和结直肠癌器官模型-微流控芯片以及多器官模型-微流控芯片。本文还概述了与设计相关的当前发展情况，能否容纳一个或多个"器官"以及相关挑战、微流控特性、细胞来源、是否用于药物测试等。重要的是，作者还讨论了它们在药物开发方面的贡献、在精准医学领域中的重要临床转化、FDA批准的模型，以及器官-芯片技术在药物研究和开发成本方面的影响。采用创作共用署名许可证。

Microfluidic organoids-on-a-chip models of human gastrointestinal systems have been established to recreate adequate microenvironments to study physiology and pathophysiology. In the effort to find more emulating systems and less costly models for drug screening or fundamental studies, gastrointestinal system organoids-on-a-chip (GOoC) have arisen as promising pre-clinical in vitro model. This progress has been built on the latest developments of several technologies such as bioprinting, microfluidics, and organoid research. In this review we will focus on healthy and disease models of: Human Microbiome-on-a-chip and its rising correlation with gastro pathophysiology; Stomach-on-a-chip; Liver-on-a-chip; Pancreas-on-a-chip; Small Intestine, Colon and Colorectal cancer organoids-on-a-chip and Multi-Organoids-on-a-chip. The current developments related to the design, ability to hold one or more "organs" and its challenges, microfluidic features, cell sources and whether they are used to test drugs are overviewed herein. Importantly, their contribution in terms of drug development and eminent clinical translation in precision medicine field, FDA approved models, and the impact of organoid-on-chip technology in terms of pharmaceutical research and development costs are also discussed by the authors.Creative Commons Attribution license.